UroGen Pharma First Quarter 2025 Earnings: Misses Expectations

UroGen Pharma (NASDAQ:URGN) First Quarter 2025 Results

Key Financial Results

• Revenue: US$20.3m (up 7.8% from 1Q 2024).
• Net loss: US$43.8m (loss widened by 36% from 1Q 2024).
• US$0.93 loss per share.

We've discovered 2 warning signs about UroGen Pharma. View them for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

UroGen Pharma Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 4.6% from a week ago.

Risk Analysis

Be aware that UroGen Pharma is showing 2 warning signs in our investment analysis and 1 of those can't be ignored...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.